Providers
Ten Questions Worth Asking a GLP-1 Telehealth Provider in 2026
The questions that mattered during the compounding era were mostly about price. After the shortage resolution closed that market, the questions that matter are about legal basis, pharmacy identity, and what happens to your money. A provider that answers all ten of these in writing has told you something real; one that will not name its pharmacy before payment has told you something too.
Key takeaways
- The useful questions changed when the compounded market closed.
- Legal basis and pharmacy identity now matter more than headline price.
- Cancellation and refund terms are unverified across our entire provider dataset.
- Get answers in writing — a sales-channel assurance is not a contractual term.
- An unwillingness to answer is itself informative.
| Questions | 10 |
|---|---|
| Most important | What is dispensed, and under what legal basis |
| Second | Which pharmacy, and what is its state licence |
| Verified across dataset | Pricing only |
| Unverified across dataset | Pharmacy, clinicians, states, dose coverage, cancellation |
| Format | Ask in writing; keep the reply |
Why did the questions change?
Because the product did. During the shortage, compounded tirzepatide was lawfully available under an explicit exemption and the meaningful variation between providers was price and service. With that exemption gone, the first question is what is actually being supplied — an approved product, a compounded preparation under a contested legal theory, or something else.
A provider that cannot answer that clearly is not one whose price is worth comparing.
| # | Question | What a good answer looks like |
|---|---|---|
| 1 | What product is dispensed — approved or compounded? | A specific product name, not a category |
| 2 | If compounded, what is the legal basis? | A clear explanation, not a deflection |
| 3 | Which pharmacy dispenses, and what is its state licence number? | A named entity and a number you can check |
| 4 | Is that pharmacy 503A or 503B? | A direct answer |
| 5 | What is the recurring price after any introductory period? | One figure, in writing |
| 6 | What mandatory fees apply on top? | A complete list |
| 7 | What does it cost at 10 mg and 15 mg? | A dose-price schedule |
| 8 | How do I cancel, and what notice is required? | A stated process and period |
| 9 | Are prepaid months refundable? | A yes or no, with terms |
| 10 | Which licensed clinician is responsible for my care? | A named clinician, contactable |
| Group | Providers |
|---|---|
| Pricing captured | 24 |
| Recurring all-in price verified | 5 |
| Pharmacy identity verified | 0 |
| Clinicians named | 0 |
| States served verified | 0 |
| Cancellation terms verified | 0 |
Why insist on written answers?
Because terms govern disputes and conversations do not. A sales representative's assurance that prepaid months are refundable carries no weight against contractual terms saying otherwise, and the moment you need that assurance is precisely the moment it becomes contested.
Written answers cost the provider nothing if the answers are accurate. Reluctance to supply them is the signal, not the inconvenience.
What should you do with the answers?
Check the checkable ones. A pharmacy licence number can be verified against the licensing state board's public register in a few minutes, and a 503B claim can be checked against the FDA's outsourcing facility list. Those two checks distinguish a verifiable supply chain from an assertion.
If a provider's answers differ from what this site publishes, that is a correction we want. Send the documentation and the record gets updated with a dated note.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on telehealth glp-1 questions to ask.
- A change to FDA labelling or regulatory position affecting a statement above.
- A verified correction accepted through the corrections process.
- A material change to a captured price, term, or programme condition.
More from the journal: all pieces
What are the limits of what this page can tell you?
Every page on this site rests on a specific published evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a qualified professional.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on ten questions worth asking a glp-1 telehealth provider in 2026.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 4 technical terms this page uses, including 503A, 503B, GLP-1, compounded — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
Frequently asked questions
What is the most important question to ask?
What product is actually dispensed and, if compounded, under what legal basis.
Why does the pharmacy name matter?
Because for any compounded preparation the pharmacy is the quality control, and its licence is independently checkable.
What if a provider will not answer?
Treat the refusal as information. These are ordinary questions with ordinary answers.
Can I verify a pharmacy licence myself?
Yes — state boards of pharmacy publish licence registers, and the FDA publishes a 503B outsourcing facility list.
Are cancellation terms published anywhere?
Rarely before checkout, which is why they are unverified across our entire provider dataset.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.